Sodium-glucose transport protein 2 inhibitors and the recently approved nonsteroidal mineralocorticoid receptor antagonist finerenone have demonstrated kidney- and heart-protective effects, which may reduce CKD-related hospitalizations.44 The gene discussed is NR3C2; the disease is chronic kidney disease.